213 related articles for article (PubMed ID: 24037346)
41. A controlling nutritional status score is an independent predictor for patients with newly diagnosed nasal-type extranodal NK/T-cell lymphoma based on asparaginase-containing regimens.
Wu W; Ren K; Chen X; Li N; Zhou H; Jiang M; Yu Y; Zou L
Cancer Med; 2023 Apr; 12(8):9439-9448. PubMed ID: 36866811
[TBL] [Abstract][Full Text] [Related]
42. 18F-FDG PET/CT for Prognostic Stratification of Patients With Extranodal Natural Killer/T-Cell Lymphoma.
Qin C; Yang S; Sun X; Xia X; Li C; Lan X
Clin Nucl Med; 2019 Mar; 44(3):201-208. PubMed ID: 30624268
[TBL] [Abstract][Full Text] [Related]
43. [Analysis on Clinical Characteristics and Prognosis of 47 Patients with Extranodal NK/T Cell Lymphoma].
Li QH; Yang P; Wang JJ; Dong F; Tian L; Wan W; Ke XY; Jing HM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Feb; 29(1):86-90. PubMed ID: 33554802
[TBL] [Abstract][Full Text] [Related]
44. Treatment outcomes of and prognostic factors for definitive radiotherapy with and without chemotherapy for Stage I/II nasal extranodal NK/T-cell lymphoma.
Yang CW; Wang CW; Hong RL; Tsai CL; Yao M; Tang JL; Lin CW; Cheng AL; Kuo SH
J Radiat Res; 2017 Jan; 58(1):114-122. PubMed ID: 27534792
[TBL] [Abstract][Full Text] [Related]
45. Persistent peripheral blood EBV-DNA positive with high expression of PD-L1 and upregulation of CD4 + CD25 + T cell ratio in early stage NK/T cell lymphoma patients may predict worse outcome.
Li PF; Mao YZ; Bai B; Gao Y; Zhang YJ; Li ZM; Jiang WQ; Huang HQ
Ann Hematol; 2018 Dec; 97(12):2381-2389. PubMed ID: 30116872
[TBL] [Abstract][Full Text] [Related]
46. The prognostic value of controlling nutritional status (CONUT) score-based nomogram on extranodal natural killer/T cell lymphoma patients.
Zhang S; Sun C; Chen X; Li D; Hu L; Zhang M; Zhang X; Zhang H; Ye J; Wang L; Jia T; Zhu T; Miao Y; Wang C; Wang L; Yan D; Shen Z; Sang W
Ann Hematol; 2023 Jun; 102(6):1433-1442. PubMed ID: 37074377
[TBL] [Abstract][Full Text] [Related]
47. [Prognostic value of pretreatment (18)F-FDG PET-CT metabolic parameters in patients with advanced extranodal NK/T cell lymphoma].
Wu LL; Liang JH; Wang L; Xu W; Ding CY
Zhonghua Zhong Liu Za Zhi; 2019 Nov; 41(11):831-836. PubMed ID: 31770850
[No Abstract] [Full Text] [Related]
48. Body mass index as a prognostic factor in patients with extranodal natural killer/T-cell lymphoma, nasal type.
Liu J; Deng YT; Zhang L; Li N; Jiang M; Zou LQ; Jiang Y
Oncotarget; 2016 Nov; 7(47):78159-78167. PubMed ID: 27556299
[TBL] [Abstract][Full Text] [Related]
49. Elevated soluble IL-2Rα, IL-8, and MIP-1β levels are associated with inferior outcome and are independent of MIPI score in patients with mantle cell lymphoma.
Sonbol MB; Maurer MJ; Stenson MJ; Allmer C; LaPlant BR; Weiner GJ; Macon WR; Cerhan JR; Witzig TE; Gupta M
Am J Hematol; 2014 Dec; 89(12):E223-7. PubMed ID: 25164110
[TBL] [Abstract][Full Text] [Related]
50. Prognostic impact of absolute lymphocyte count/absolute monocyte count ratio and prognostic score in patients with nasal-type, extranodal natural killer/T-cell lymphoma.
Li N; Zhang L; Song HL; Zhang J; Weng HW; Zou LQ
Tumour Biol; 2017 May; 39(5):1010428317705503. PubMed ID: 28475009
[TBL] [Abstract][Full Text] [Related]
51. Prognostic significance of locally invaded sites and tissue types in patients with nasal extranodal natural-killer/T-cell lymphoma: a single-center retrospective analysis.
Dong GH; Li Y; Dong JY; Li X; Wan HF; Yang L; Wang JW; Gong LP; Zhao YH; Zhang H; Gao ZF; Liu HG
Chin Med J (Engl); 2019 Jun; 132(11):1305-1313. PubMed ID: 31009392
[TBL] [Abstract][Full Text] [Related]
52. Predicting treatment response of patients with extranodal natural killer/T-cell lymphoma based on levels of PD-L1 mRNA and soluble PD-L1.
Feng Y; Jing C; Yu X; Cao X; Xu C
Hematol Oncol; 2020 Oct; 38(4):467-477. PubMed ID: 32515093
[TBL] [Abstract][Full Text] [Related]
53. CD30 expression in extranodal natural killer/T-cell lymphoma, nasal type among 622 cases of mature T-cell and natural killer-cell lymphoma at a single institution in South China.
Feng Y; Rao H; Lei Y; Huang Y; Wang F; Zhang Y; Xi S; Wu Q; Shao J
Chin J Cancer; 2017 May; 36(1):43. PubMed ID: 28486951
[TBL] [Abstract][Full Text] [Related]
54. Cutaneous extranodal natural killer/T-cell lymphoma: a comparative clinicohistopathologic and survival outcome analysis of 45 cases according to the primary tumor site.
Lee WJ; Jung JM; Won CH; Chang SE; Choi JH; Chan Moon K; Park CS; Huh J; Lee MW
J Am Acad Dermatol; 2014 Jun; 70(6):1002-9. PubMed ID: 24629518
[TBL] [Abstract][Full Text] [Related]
55. A New Prognostic Index for Extranodal Natural Killer/T-Cell Lymphoma:Incorporation of Serum β-2 Microglobulin to PINK.
Kang S; Cho H; Kim S; Lee K; Kang EH; Park JS; Lee YS; Park CS; Go H; Huh J; Ryu JS; Lee SW; Kim SJ; Kim WS; Yoon SE; Ko YH; Suh C
Cancer Res Treat; 2023 Jan; 55(1):314-324. PubMed ID: 35381163
[TBL] [Abstract][Full Text] [Related]
56. Primary site and regional lymph node involvement are independent prognostic factors for early-stage extranodal nasal-type natural killer/T cell lymphoma.
Niu SQ; Yang Y; Li YY; Wen G; Wang L; Li ZM; Wang HY; Zhang LL; Xia YF; Zhang YJ
Chin J Cancer; 2016 Apr; 35():34. PubMed ID: 27044275
[TBL] [Abstract][Full Text] [Related]
57. The prognostic nutritional index predicts survival for patients with extranodal natural killer/T cell lymphoma, nasal type.
Chen KL; Liu YH; Li WY; Chen J; Gu YK; Geng QR; Jiang WQ; Huang HQ; Lin TY; Xia ZJ; Cai QQ
Ann Hematol; 2015 Aug; 94(8):1389-400. PubMed ID: 25869028
[TBL] [Abstract][Full Text] [Related]
58. Prognostic indicators of survival in sinonasal extranodal natural killer/T-cell lymphoma.
Varelas AN; Ganti A; Eggerstedt M; Tajudeen BA
Laryngoscope; 2019 Dec; 129(12):2675-2680. PubMed ID: 30801751
[TBL] [Abstract][Full Text] [Related]
59. The Clinical Features and Survival Outcome of 107 Newly Diagnosed Advanced Stage Extranodal NK/T-Cell Lymphoma Cases: A Triple-Center Study.
Li J; Li J; Zhong M; Zhou H; Yu B
Cancer Manag Res; 2021; 13():1541-1549. PubMed ID: 33623433
[TBL] [Abstract][Full Text] [Related]
60. High level of soluble interleukin-2 receptor in serum predicts treatment resistance and poor progression-free survival in multiple myeloma.
Wang L; Wang JH; Liu WJ; Wang WD; Wang H; Chen XQ; Geng QR; Lu Y; Xia ZJ
Ann Hematol; 2017 Dec; 96(12):2079-2088. PubMed ID: 28871325
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
